Skip to main content

Day: February 4, 2022

Drawdown of an Advance Pursuant to Financing Arrangement Between Valoe Corporation and Riverfort

Valoe Corporation                Stock Exchange Release 4 February 2022 at 12.15 Finnish time                                  Further to the announcement of 30 July 2021, Valoe Corporation (“Valoe”) has completed the drawdown of an advance of EUR 300,000, pursuant to the terms and conditions of the Financing Agreement between Valoe and RiverFort Global Opportunities Pcc Limited (“RiverFort”). Following the drawdown of the advance Valoe will grant 931,677 warrants to RiverFort. Valoe has settled transaction fees of EUR 27,000 by the transfer of a total of 335,404 treasury shares. Valoe and RiverFort have separately agreed to reduce the outstanding balance of the Advances withdrawn earlier by approx. EUR 0.1 million including part of the principal and interests of the Advances through RiverFort electing to subscribe for shares in Valoe....

Continue reading

Atotech Names Klaus-Günter Vennemann to Board of Directors; Brian Bernasek Resigns as Director

BERLIN, Feb. 04, 2022 (GLOBE NEWSWIRE) — Atotech (NYSE: ATC), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, announced today that Brian Bernasek, a member of the company’s Board of Directors, has resigned as a director as of January 31, 2022. The Board has appointed Klaus-Günter Vennemann as a Director and a member of the Board’s Audit Committee, effective February 1, 2022. Mr. Vennemann is a management consultant and a member of the Supervisory Board of Rheinmetall since 2016. He was previously the CEO of the General Lighting business unit of OSRAM AG. The Board has determined that Mr. Vennemann is an independent director within the meaning of the New York Stock Exchange listing standards. About AtotechAtotech is a leading specialty chemicals technology company and a...

Continue reading

PRESS RELEASE: BIGBEN: Confirmation of the distribution ratio and implementation of the exceptional distribution in kind of Nacon shares

Bigben                                                        Press release Lesquin, 4 February 2022, 11hrs Confirmation of the distribution ratio and Implementation of the exceptional distribution in kind of Nacon shares BIGBEN INTERACTIVE (“BBI” or the “Company”) informs its shareholders that given the opening price of Nacon shares on the regulated market of Euronext in Paris, its Board of Directors meeting today confirmed the distribution ratio of one (1) Nacon share for every five (5) BBI shares held. Following the approval of the transaction by BBI’s shareholders at the Combined General Meeting on January 28, 2022, the exceptional distribution in kind of Nacon shares to BBI’s shareholders is effective as of today, the date of the payment. Following this transaction, BBI will hold 61,244,666 Nacon...

Continue reading

Fortuna pursues clarification from Mexican authorities on term of the Environmental Impact Authorization

VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that on January 28, 2022 it received a notice (the “Notice”) from the Secretaría de Medio Ambiente y Recursos Naturales (“SEMARNAT”) which advised that SEMARNAT has made a typographical error in the extension to the term of the environmental impact authorization (“EIA”) for the San Jose Mine, located in Oaxaca, Mexico. On December 17, 2021, SEMARNAT granted the Company a 12 year extension (the “EIA Extension”) to the EIA for the San Jose Mine (refer to Fortuna news release dated December 20, 2021) which expires in October 2033. However, the Notice states that SEMARNAT has made a typographical error in the EIA Extension and that the correct term is two years. The Company is of the view that the Notice was issued...

Continue reading

Terranet Announces CEO’s Termination with Immediate Effect

Lund, February 4, 2022. Terranet AB (Nasdaq: TERRNT-B), a tech company that provides advanced driver assistance systems (ADAS) for the automotive industry announced today that the Board of Directors has terminated Pär-Olof Johannesson’s employment as CEO of Terranet AB (publ.) (“Terranet”) with immediate effect. Terranet’s Chairman Göran Janson has taken over as interim CEO until a successor is put in place. Göran Janson has a long and successful career with advanced tech companies and leading global organizations. The process of recruiting a successor CEO that will lead the company on its continued growth journey, has been initiated. For more information: Göran Janson Chairman of the Board goran.janson@terranet.se Thomas Falkenberg  CFO thomas.falkenberg@terranet.se+ 46 703 360 346  About Terranet Terranet AB (Nasdaq: TERRNT-B). With...

Continue reading

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhibitor targeting fibroblast growth factor receptors (“FGFR”) 1/2/3, in combination with chemotherapy or the anti-PD-1 therapy, toripalimab. The first patient received their first dose on January 22, 2022. The clinical trial is a multi-center, two-stage, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-453 combination therapy in patients with specific advanced or metastatic solid tumors. The first stage of the study is a dose escalation phase to determine the dose limiting toxicity (DLT) and recommended...

Continue reading

SpareBank 1 SMN: SpareBank 1 Gruppen – result 4th quarter and the final year end of 2021

SpareBank 1 SMN has an ownership share of 19.5 % in SpareBank 1 Gruppen AS. SpareBank 1 SMN’s controlling interest share of SpareBank 1 Gruppen’s profit after tax in the 4th quarter was NOK 173 (86) *million. SpareBank 1 SMN’s share of SpareBank 1 Gruppen’s profit after tax as of 31 December 2021 was NOK 471 (193) million. The SpareBank 1 Gruppen’s profit before tax as of 31 December 2021 was NOK 4,153(1,817) million. Profit after tax was NOK 3,250 (1,393) million. The controlling interest’s share of the profit in the 4th quarter and as of 31 December 2021 was resp. NOK 888(439) and NOK 2,415(988) million. Profit before and after tax in the fourth quarter was resp. NOK 1,337 (764) million and NOK 1,080 (594) million. Fremtind, which is owned 65% by SpareBank 1 Gruppen AS, had a profit before tax of NOK 678 (583) million in...

Continue reading

Alfa Beta Brand President Vassilis Stavrou to leave Ahold Delhaize

Zaandam, the Netherlands, February 4, 2022 – Vassilis Stavrou, Brand President of Alfa Beta, has decided to leave Ahold Delhaize. Stavrou started his career at the company 28 years ago, as warehouse manager. He took on roles in Quality Assurance and Food Safety afterwards, before transitioning to Human Resources. From there Stavrou transitioned to roles within Delhaize Group where he held responsibility as SVP Human Resources, Organizational Development & Sustainability and ultimately Business Development. He was then appointed Brand President for Mega Image in Romania. After which he was appointed to Brand President at Alfa Beta in Greece in 2018.  Wouter Kolk, CEO Ahold Delhaize Europe & Indonesia: “I would like to take this opportunity to thank Vassilis who made many contributions during his varied and longstanding...

Continue reading

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier at-home screening test for colorectal cancer BERKELEY, Calif. and MAINZ, Germany, Feb. 04, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has commenced ColoFuture, an international clinical study to evaluate the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer which is being commercialized across Europe. The novel gene expression (mRNA) biomarkers, which we acquired an exclusive option to in-license from the Université de Sherbrooke in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.